Langer-Gould A, Smith JB, Albers KB, Xiang AH, Wu J, Kerezsi EH et al (2020) Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Jesus-Ribeiro J, Correia I, Martins AI, Fonseca M, Marques I, Batista S et al (2017) Pregnancy in Multiple Sclerosis: a Portuguese cohort study. J Neurol 266:2512–2517įinkelsztejn A, Fragoso YD, Ferreira MLB, Lana-Peixoto MA, Alves-Leon SV, Gomes S et al (2011) The Brazilian database on pregnancy in multiple sclerosis. Mult Scler 26:69–78īerenguer-Ruiz L, Gimenez-Martinez J, Palazón-Bru A, Sempere AP (2019) Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. Neurology 90:e840–e846īsteh G, Algrang L, Hegen H, Auer M, Wurth S, Di Pauli F et al (2020) Pregnancy and multiple sclerosis in the DMT era: a cohort study in Western Austria. Ther Adv Neurol Disord 5:247–253Īlroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J (2018) Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Hellwig K, Haghikia A, Rockhoff M, Gold R (2012) Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Mult Scler 20:739–746įragoso YD, Boggild M, Macias-Islas MA, Carra A, Schaerer KD, Aguayo A et al (2013) The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A et al (2014) Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F et al (2020) Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: the POPARTMUS study. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P et al (2004) Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. This study provides class III evidence that systematic high-dose corticosteroids are not associated with a reduced inflammatory activity during the post-partum period in multiple sclerosis patients.Ĭonfavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Our primary outcomes were not statistically different between both groups. For both groups, the annualized relapse rate decreased during pregnancy (0.28 in treating centers and 0.34 in non-treating centers during the third trimester) and increased during the first post-partum trimester (0.45 and 0.69, respectively) with 11% and 14% (NS) of patients facing at least one relapse, respectively. Resultsģ50 patients were included (116 from treating centers, 234 from non-treating centers). Our primary outcomes were the time from delivery to first relapse, EDSS progression and MRI activity between patients of treating centers and non-treating centers, after propensity-score weighting.
We included relapsing–remitting multiple sclerosis women who delivered between January 2007 and January 2017. We selected five French Multiple Sclerosis centers using the same post-partum strategy for their patients-either high-dose steroids (treating centers TC) or no treatment (non-treating centers NTC). To assess the effectiveness of preventive high-dose corticosteroids in the post-partum period by comparing two strategies: (1) no preventive treatment and (2) standardized preventive treatment. No specific treatment has demonstrated its effectiveness to prevent post-partum relapses for multiple sclerosis (MS) women.